Moroxite announced FDA Breakthrough Device Designation for Xerafuse TOB, a resorbable graft-extending material that releases the antibiotic tobramycin, intended to extend bone graft in lumbosacral spinal fusion in patients at higher risk of infection. It is the company's second designation, after Xerafuse BMP in 2025. A designation gives closer contact with FDA and prioritised review; it is not a clearance or approval.
- Type
- FDA decision
- Company
- Moroxite (Sweden)
- Device
- Xerafuse TOB antibiotic-releasing bone graft extender
- Date
- 17 November 2026
- Jurisdiction
- US
- Classification
- FDA Breakthrough Device Designation (not a clearance)
- Source
- Moroxite press release
Official source →Source checked